Wednesday, July 8, 2026

pharma · Renal Impairment · Urinary Tract Infection · SPRO

Spero Therapeutics

Spero Therapeutics clinical programs — 2 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

675 Massachusetts Ave, 14th Floor, Cambridge, MA 02139, US HQ
2013 Founded
45 Employees
Public company Type
SPRO · NYSE Ticker
Company details
Status
Public
HQ
675 Massachusetts Ave, 14th Floor, Cambridge, MA 02139, US
Founded
2013
Employees
45
Programs
21
Drugs
9
Patents
16
Intelligence · Clinical Programs

Spero Therapeutics projects

2 ClinicalTrials.gov programs sponsored by Spero Therapeutics.

Spero Therapeutics has 2 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. Placebo

    Spero Therapeutics

    Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD)

    phase 2 small molecule completed

    1 trial
  2. SPR720

    Spero Therapeutics

    Mycobacterium Avium Complex

    phase 2 small molecule terminated

    1 trial

Frequently asked questions

How many clinical projects does Spero Therapeutics have?

2 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.